BioCentury | Mar 29, 2019
Clinical News

Velicept's overactive bladder therapy meets in Phase IIb

...Velicept said solabegron met the primary endpoint in the Phase IIb VEL-2002 trial to treat overactive...
...β 3 (ADRB3) agonist early next year. In 435 women ages 18-80 with OAB, twice-daily solabegron...
...the potential for best-in-class efficacy and improved safety for patients with OAB." Brian Moy, Assistant Editor solabegron (GW427353) Velicept...
BioCentury | Oct 19, 2018
Financial News

Velicept raises additional $15M in series B

...is Velicept's founding investor. The company intends to complete two Phase IIb trials of solabegron (GW427353...
..."Velicept Raises First Tranche of $21M Series B" ). Velicept Therapeutics Inc., Malvern, Pa. Shannon Lehnbeuter solabegron (GW427353) Velicept...
BioCentury | Dec 2, 2015
Financial News

Velicept raises first tranche of $21M series B

...a Phase II study of adrenergic receptor beta 3 ( ADRB3 ) agonist solabegron ( GW427353...
...NeXeption formed Velicept in June. The newco subsequently merged with AltheRx Pharmaceuticals Inc., which acquired solabegron...
BioCentury | Jul 27, 2015
Company News

AltheRx, Velicept deal

...AltheRx, and the surviving company will retain Velicept’s name and focus on the development of solabegron...
BioCentury | May 3, 2013
Financial News

AltheRx raises $15M, names new CEO

...the company's solabegron . This year, AltheRx plans to start a Phase III trial of solabegron...
BioCentury | Mar 5, 2012
Clinical News

Solabegron: Phase II data

...trial in 258 women with moderate to severe OAB symptoms showed that twice-daily 125 mg solabegron...
...start a Phase IIb/III trial evaluating twice-daily 125 mg solabegron to treat OAB this year. Solabegron...
...sum (see BioCentury, March 28, 2011). AltheRx Pharmaceuticals Inc. , Malvern, Pa. Product: Solabegron ( GW427353...
BioCentury | Mar 2, 2012
Clinical News

AltheRx's solabegron meets overactive bladder endpoint

...AltheRx Pharmaceuticals Inc. (Malvern, Pa.) said solabegron met the primary endpoint of reducing the mean number...
...start a Phase IIb/III trial evaluating twice-daily 125 mg solabegron to treat OAB this year. Solabegron...
BioCentury | Mar 28, 2011
Company News

AltheRx Pharmaceuticals Inc., GlaxoSmithKline deal

...AltheRx acquired solabegron ( GW427353 ) from GlaxoSmithKline for an undisclosed sum. AltheRx plans to begin...
BioCentury | Mar 24, 2011
Company News

AltheRx acquires Solabegron from GSK

...AltheRx Pharmaceuticals Inc. (Chadds Ford, Pa.) acquired Solabegron ( GW427353 ) from GlaxoSmithKline plc (LSE:GSK; NYSE:GSK...
BioCentury | May 28, 2002
Product Development

Going for the insulin pill

...pharma company has two beta3 adrenergic agonists in Phase I testing for Type II diabetes: GW427353...
Items per page:
1 - 10 of 10